Mirxes Holding Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2629)

(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; (2) DELAY IN HOLDING OF ANNUAL GENERAL MEETING; AND (3) CONTINUED SUSPENSION OF TRADING

This announcement is made by Mirxes Holding Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.24A of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcements of the Company dated March 31, 2026, April 2, 2026, April 30, 2026 and May 10, 2026 (collectively, the "**Announcements**") in relation to, amongst others, the delay in publication of the annual results announcement and delay in despatch of the annual report for the year ended December 31, 2025, the establishment of the independent investigation committee (the "**IIC**"), the suspension of trading in the shares of the Company, the outstanding audit matters raised by the Company's auditor (the "**Outstanding Audit Matters**"), and the Resumption Guidance. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS

As disclosed in the announcement of the Company dated April 30, 2026, the Stock Exchange has set out the following Resumption Guidance (a) to (f) for the Company:

Resumption Guidance (a): conduct an appropriate independent forensic investigation into the Prepayments, the material cash outflows subsequent to December 31, 2025 and any other payments of a similar nature or giving rise to similar concerns, assess the impact on the Company's business operations and financial position, announce the findings and take appropriate remedial actions

As disclosed in the Company's announcement dated April 2, 2026, the IIC was established to oversee and supervise the independent investigation (the "**Investigation**") for the purpose of addressing the Outstanding Audit Matters. The Investigation has commenced promptly thereafter. On April 27, 2026, the Company received the Resumption Guidance from the Stock Exchange. The IIC is in discussion with the Board to review and adjust (where necessary) the scope of the Investigation to ensure alignment with the Resumption Guidance. As at the date of this announcement, the Investigation is ongoing. Further announcement(s) will be made by the Company regarding the progress of the Investigation as and when appropriate.

Resumption Guidance (b): demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence

As at the date of this announcement, nothing has come to the attention of the Company which leads to any concern over the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence. Further announcement(s) will be made by the Company in relation to the status and development in this regard as and when appropriate.

Resumption Guidance (c): engage an independent internal control consultant to conduct an independent internal control review and demonstrate that (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the issuer to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information

The Board has approved the appointment of an independent external adviser to review the Group's internal control systems and its effectiveness (the "**Internal Control Review**"). The scope of the Internal Control Review initially covers, amongst other things, procurement and treasury, and may expand to other aspects depending on the outcome of the Investigation. The Company will make further announcement(s) as and when there are material developments in relation to the Internal Control Review.

Resumption Guidance (d): publish all outstanding financial results required under the Listing Rules and address any audit modifications

The Company is actively cooperating with the IIC to address the Outstanding Audit Matters so that it can resume work on the 2025 Annual Results and the 2025 Annual Report as soon as possible. Further announcement(s) will be made by the Company regarding the publication of the 2025 Annual Results and the dispatch of the 2025 Annual Report as and when appropriate.

Resumption Guidance (e): demonstrate the Company's compliance with Rule 13.24 of the Listing Rules

The Group is principally engaged in the research, development, manufacturing and commercialization of molecular diagnostic tests, with a focus on early cancer detection. To the best knowledge of the Directors, as at the date of this announcement, the business operations of the Group are continuing as usual in all material respects. Based on preliminary assessment, the Board is of the view that the Prepayments and the Material Cash Outflows should have no significant adverse impact on the business operations of the Group. On such basis, the Board is of the view that the Group is carrying out, and will continue to carry out, a business with a sufficient level of operations and assets of sufficient value to support its operations to warrant the continued listing of the Company's shares.

Resumption Guidance (f): inform the market of all material information for the Shareholders and investors to appraise the Company's position

Since the suspension of trading in the shares of the Company, the Company has been updating the Shareholders and potential investors with material information on a regular basis by way of publication of announcements on the website of the Stock Exchange in accordance with the Listing Rules. The Company is working closely with its professional advisers with the view to taking appropriate steps to fulfill the Resumption Guidance, and will update the Shareholders and potential investors of all material information of the Company as and when appropriate.

(2) DELAY IN HOLDING OF ANNUAL GENERAL MEETING

Pursuant to Rule 13.46(2)(b) of the Listing Rules, the Company should lay its annual financial statements before the shareholders of the Company (the "**Shareholders**") at its annual general meeting within the period of six months after the end of the financial year or accounting reference period to which the annual financial statements relate (i.e., on or before June 30, 2026). Pursuant to Article 62 of the Company's third amended and restated articles of association, the Company shall hold a general meeting as its annual general meeting within six months after the end of each financial year (i.e., on or before June 30, 2026). Following the delay in publication of the 2025 Annual Results and delay in dispatch of the 2025 Annual Report, the convening of the annual general meeting of the Company will be postponed beyond six months from the financial year end date. The Company will publish further announcement(s) to inform Shareholders of the date of the annual general meeting as and when appropriate.

(3) CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will remain suspended pending the fulfillment of the Resumption Guidance as specified by the Stock Exchange.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, July 1, 2026

As at the date of this announcement, the executive Directors are Dr. ZHOU Lihan and Dr. ZOU Ruiyang; the non-executive Directors are Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da; and the independent non-executive Directors are Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Mr. TSANG Kwok Wai.